TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23901669
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (Avastin)
Study: 22789792
Drug: Aromatherapy (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (inhalation group or aromatherapy hand technique) with essential oil blend of rose otto and lavandula angustifolia @ 2% dilution, 15 min sessions, twice a week for four weeks
Study: 19165115
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment for 2 weeks
Study: 17565326
Drug: Thymoglobulin induction
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin induction with tacrolimus, mycophenolate, and steroids
Study: 11473908
Drug: Webster‐Stratton basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Webster‐Stratton basic videotape programme administered to parents of six to eight children over 13‐16 weeks
Study: 9870319
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) therapy duration
Study: 3132574
Drug: met‐hGH in
Approvals — FDA: no, EMA: no, PMDA: no
Description: met‐hGH in intravenous feeding
Study: 31599561
Drug: Postoperative hypocalcemia
Normalized name: Drugs for treatment of hypercalcemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative hypocalcemia (<8.5 mg/dL)
Study: 31599561
Drug: Severe hypocalcemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hypocalcemia (<7.5 mg/dL)
Study: 28665377
Drug: Pharmacopuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopuncture treatment with anti-homotoxic agents (placental compositum, co-enzyme compositum, ubichinon compositum)
Study: 28665377
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including histamine H2-receptor antagonists, proton pump inhibitors, stimulators of gastrointestinal motility, alginates, and other drugs
Study: 21348539
Drug: Vicriviroc with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc with ritonavir and protease inhibitors (fixed-sequence studies)
Study: 21348539
Drug: Vicriviroc with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc with other antiretroviral agents
Study: 21348539
Drug: Vicriviroc and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc and combination treatment
Study: 21348539
Drug: Vicriviroc co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc co-administered with antiretroviral agents
Study: 18509176
Drug: Docetaxel therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel therapy in ER-positive patients
Study: 18509176
Drug: Docetaxel therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel therapy in ER-negative patients
Study: 10737286
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (mean dose approximately 40 mg/d after titration)
Study: 8762741
Drug: District drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: District drug formulary
Study: 18050628
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min acupuncture treatment
Study: 18050628
Drug: 40 min
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL STICK [Brush On Block Quick Stick SPF 40 Mineral Stick]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 min acupuncture treatment
Study: 18050628
Drug: 60 min
Normalized name: TITANIUM DIOXIDE 6 g in 100 g / ZINC OXIDE 4.6 g in 100 g TOPICAL STICK [SPF 60 Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 min acupuncture treatment
Study: 18050628
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (all groups)
Study: 15929963
Drug: Predicted R(L)
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted R(L) from X(rs)
Study: 12593524
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 3,000-4,000 microg/day b.i.d. via nebulizer
Study: 12593524
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) spray 1,500-2,000 microg/day b.i.d. via metered-dose inhaler (MDI) plus spacer
Study: 8712434
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1 microgram/kg
Study: 1986567
Drug: EPO (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (2,000 U IV three times a week) + nandrolone decanoate (100 mg IM weekly)
Study: 30428891
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - typical daily clinical practice
Study: 11748952
Drug: Micronised purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised purified flavonoid fraction (MPFF) 500 mg twice daily for 60 days
Study: 11748952
Drug: Placebo 500
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg twice daily for 60 days
Study: 9709879
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD) 4 mg/(kg.d)
Study: 9709879
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.8 mg/(kg.d)
Study: 7654480
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporin (Neoral), 10 mg kg‐1
Study: 7654480
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral formulation of cyclosporin (Sandimmun), 10 mg kg‐1
Study: 7654480
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporin (Neoral)
Study: 364615
Drug: Ketoprofen (50+50+100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (50+50+100 mg)
Study: 364615
Drug: Naproxen (250+250+250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250+250+250 mg)
Study: 31850976
Drug: Compression stockings
Normalized name: Truform Medical Compression Stockings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression stockings for 7 days (with concurrent phlebectomies)
Study: 29654563
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste (TAP) with minocycline
Study: 29654563
Drug: TAP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP with amoxicillin
Study: 21810649
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (valproate) at a target dose of 10 to 12 mg per kilogram of body weight per day for 24 months
Study: 19265311
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg combined with dexamethasone 10 mg
Study: 17040215
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg single dose) taken 12 hours prior to melatonin intake
Study: 17040215
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg single dose) taken 24 hours prior to melatonin intake
Study: 17040215
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg orally)
Study: 17040215
Drug: Melatonin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin as a probe drug
Study: 9161648
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial gel containing cetrimide, bacitracin, and polymyxin B sulfate
Study: 9161648
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine antiseptic cream
Study: 7967362
Drug: Torasemide alone
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide alone (50 mg i.v.)
Study: 7967362
Drug: Torasemide +
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide + Butizid (20 mg i.v.)
Study: 3307643
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of desmopressin tablet
Study: 3307643
Drug: Desmopressin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (both oral and nasal)
Study: 30098126
Drug: Inulin-propionate ester
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin-propionate ester (IPE) 20 g/d for 42 days
Study: 25271185
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg i.m. ketamine
Study: 25271185
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.m. morphine
Study: 23710492
Drug: Natamycin (5%)
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natamycin (5%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Study: 23710492
Drug: Voriconazole (1%)
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole (1%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Study: 8431570
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS) 1 g/patient
Study: 3298752
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 37.5 mg/day
Study: 3298752
Drug: Carteolol (CAR)
DrugBank: Carteolol (DB00521)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carteolol (CAR) 15 mg/day
Study: 29807307
Drug: Combo stent
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combo stent (dual-therapy CD34 antibody-covered sirolimus-eluting stent)
Study: 22676921
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of oxytocin 10 IU via Uniject™ by Community Health Officers within one minute of delivery
Study: 20028969
Drug: Low-insulin high-glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-insulin high-glucose (LIHG; variable insulin, BG of 7-9 mmol/l)
Study: 20028969
Drug: High-insulin high-glucose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-insulin high-glucose (HIHG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 7-9 mmol/l)
Study: 20028969
Drug: High-insulin low-glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-insulin low-glucose (HILG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 4-6 mmol/l)
Study: 9714962
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture on permucosal dental implants
Study: 9714962
Drug: Overdenture on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture on a transmandibular implant
Study: 7848789
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean final daily dose 2.9 mg)
Study: 30293128
Drug: Functional behavior-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional behavior-based cognitive behavior therapy (Fb-CBT)
Study: 26525623
Drug: Generic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic medication (memantal)
Study: 22968256
Drug: Low-dose ALN
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ALN (70 mg every two weeks)
Study: 22968256
Drug: Standard-dose ALN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ALN (70 mg weekly)
Study: 18237377
Drug: Postal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postal administration
Study: 12610178
Drug: Irinotecan weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan weekly (125 mg/m²)
Study: 12610178
Drug: Irinotecan once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan once every 3 weeks (350 mg/m² or 300 mg/m² for specific patients)
Study: 9059214
Drug: rocuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.1 mg kg‐1 (group R1)
Study: 9059214
Drug: rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.3 mg kg‐1 (group R3)
Study: 8437693
Drug: High-dose piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose piracetam (8 g/d per os)
Study: 24841974
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 every 3 weeks)
Study: 24841974
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) in EGFR wild-type tumors
Study: 24841974
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 every 3 weeks) in EGFR wild-type tumors
Study: 22290901
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol + remifentanil
Study: 22290901
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with sevoflurane
Study: 19004511
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg, p.o., o.d. (n=13)
Study: 18317188
Drug: Tantalum implant
Normalized name: tantalum
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tantalum implant
Study: 8834341
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GP) 1.0 mg
Study: 8834341
Drug: Nebulized metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized metaproterenol (MP) 15 mg
Study: 8834341
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GP 1.0 mg and MP 15 mg (GP+MP)
Study: 8834341
Drug: Control (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (either drug alone)
Study: 3931899
Drug: Central parenteral
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central parenteral nutrition (CPN) for 4 weeks
Study: 3931899
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN) for 4 weeks
Study: 3931899
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) (weeks 1‐4)
Study: 30799266
Drug: 30 5-mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 5-mg oxycodone immediate-release (OxyIR) pills
Study: 30799266
Drug: 90 5-mg
Normalized name: sulfacetamide sodium 90 MG/ML / sulfur 42.5 MG/ML [Clenia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 5-mg oxycodone immediate-release (OxyIR) pills
Study: 26511996
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg TCZ+MTX
Study: 26511996
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg TCZ+placebo
Study: 26511996
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg TCZ+MTX
Study: 24342385
Drug: PT +
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT + STIM (44.8 ± 14.6 mg/day) + placebo (1.88 mg/day ± 0.72)
Study: 24342385
Drug: PT +
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT + STIM (46.1 ± 16.8 mg/day) + risperidone (1.65 mg/day ± 0.75)
Study: 22267714
Drug: Vitamin D3,
Normalized name: Vitamin D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, 50,000 IU administered at 0, 4, and 8 weeks
Study: 17106275
Drug: TMC120 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC120 vaginal microbicide gel (various concentrations)
Study: 17106275
Drug: TMC120 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC120 vaginal microbicide gel
Study: 10218041
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Study: 10218041
Drug: 0.05% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluocinonide ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Study: 10218041
Drug: Placebo (hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hydroxyethyl cellulose gel plus miconazole gel and 0.12% chlorhexidine mouthwashes)
Study: 1688495
Drug: Modified LSA2L2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified LSA2L2 therapy
Study: 31063156
Drug: 180mcg/kg/day palifermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mcg/kg/day palifermin for 3 days immediately prior to and after each cycle of alemtuzumab, with repeat doses at M1 and M3.
Study: 23510984
Drug: Conatumumab 10
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conatumumab 10 mg/kg plus FOLFIRI (Arm A)
Study: 23510984
Drug: Ganitumab 12
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 12 mg/kg plus FOLFIRI (Arm B)
Study: 14508203
Drug: Thiazide-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-based antihypertensive therapy
Study: 3893512
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine (200 mg thrice daily for 4 weeks)
Study: 31153114
Drug: NaOCl treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOCl treatment for 20 minutes
Study: 31153114
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment (200 °C)
Study: 31153114
Drug: NaOCl treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOCl treatment followed by heat treatment (200 °C)
Study: 31153114
Drug: Micro-Raman spectroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-Raman spectroscopy after NaOCl treatment
Study: 27783276
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years, with PSL starting at 40 mg/day and tapering, and MZR given once-a-day at 150 mg (group 1) or 3-times-a-day at 50 mg (group 2).
Study: 27783276
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years.
Study: 26392095
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Study: 21816786
Drug: GW501516 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW501516 (2.5 mg/d)
Study: 15292386
Drug: Epirubicin-paclitaxel (ET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-paclitaxel (ET) chemotherapy
Study: 15292386
Drug: Epirubicin-cyclophosphamide (EC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-cyclophosphamide (EC) chemotherapy
Study: 9146779
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin 6 mg/kg
Study: 9146779
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin 1 mg/kg
Study: 9146779
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (both dosages)
Study: 7995207
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin
Study: 8190679
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral ketorolac
Study: 8190679
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of IM morphine
Study: 8190679
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of IM morphine
Study: 30091317
Drug: Early targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early targeted physical rehabilitation with standard sepsis treatment during hospitalization
Study: 30091317
Drug: Standard sepsis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sepsis treatment
Study: 24137215
Drug: Dexmedetomidine (0.2‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2‐0.5 μg/kg/h continuous intravenous infusion for 12 h)
Study: 24137215
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline and isopropylphenol (2‐4 mg/kg/h intravenous infusion for postoperative sedation)
Study: 21562445
Drug: Intravenous procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procaine (2 g/24 h) for 72 hours